-
公开(公告)号：US20120014960A1
公开(公告)日：2012-01-19
申请号：US13243795
申请日：2011-09-23
Applicant: Sha MI , R. Blake Pepinsky , Christilyn Graff
Inventor： Sha MI , R. Blake Pepinsky , Christilyn Graff
IPC: A61K39/395 , A61P25/28 , C12P21/00 , C07K16/18 , C12N15/13
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6849 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody
Abstract translation: 内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体
-
公开(公告)号：US20100015131A1
公开(公告)日：2010-01-21
申请号：US12500472
申请日：2009-07-09
Applicant: Sha MI , R. Blake Pepinsky
Inventor： Sha MI , R. Blake Pepinsky
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6849 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody
Abstract translation: 内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体
-
公开(公告)号：US20090252748A1
公开(公告)日：2009-10-08
申请号：US12410181
申请日：2009-03-24
Applicant: Sha MI , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber , Steven D. Miklasz
Inventor： Sha MI , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber , Steven D. Miklasz
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。
-
公开(公告)号：US20120230979A1
公开(公告)日：2012-09-13
申请号：US13414222
申请日：2012-03-07
Applicant: Sha MI , John McCoy , R. Blake Pepinsky , Daniel H.S. Lee
Inventor： Sha MI , John McCoy , R. Blake Pepinsky , Daniel H.S. Lee
IPC: A61K39/395 , C12N15/86 , C12N5/10 , C07K19/00 , A61K31/7088 , C12N5/0793 , C07K16/42 , C12N15/113 , C12N15/12 , C12N5/12 , A61K38/02 , A61P25/28 , A61P25/00 , A61P25/16 , C12N15/13
CPC classification number: G01N33/56966 , A61K38/00 , C07K14/4702 , C07K14/70571 , C07K16/18 , C07K16/2803 , C07K2319/30 , C12N5/0619 , C12N2500/46 , G01N33/5058 , G01N33/6896
Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
Abstract translation: 本发明提供了Sp35多肽及其融合蛋白，Sp35抗体及其抗原结合片段和编码其的核酸。 本发明还提供了包含此类Sp35抗体，其抗原结合片段，Sp35多肽及其融合蛋白的制备和使用方法。
-
公开(公告)号：US20120190070A1
公开(公告)日：2012-07-26
申请号：US13356413
申请日：2012-01-23
Applicant: Sha MI , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber , Steven D. Miklasz , Christilyn Graff
Inventor： Sha MI , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber , Steven D. Miklasz , Christilyn Graff
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。
